139 related articles for article (PubMed ID: 30176355)
1. Carbapenems and alternative β-lactams for the treatment of infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: What impact on intestinal colonisation resistance?
Woerther PL; Lepeule R; Burdet C; Decousser JW; Ruppé É; Barbier F
Int J Antimicrob Agents; 2018 Dec; 52(6):762-770. PubMed ID: 30176355
[TBL] [Abstract][Full Text] [Related]
2. Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort.
Palacios-Baena ZR; Gutiérrez-Gutiérrez B; Calbo E; Almirante B; Viale P; Oliver A; Pintado V; Gasch O; Martínez-Martínez L; Pitout J; Akova M; Peña C; Molina Gil-Bermejo J; Hernández A; Venditti M; Prim N; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Giamarellou H; Almela M; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Paño-Pardo JR; Torre-Cisneros J; Souli M; Bonomo RA; Carmeli Y; Paterson DL; Pascual Á; Rodríguez-Baño J;
Clin Infect Dis; 2017 Oct; 65(10):1615-1623. PubMed ID: 29020250
[TBL] [Abstract][Full Text] [Related]
3. Quantifying antibiotic impact on within-patient dynamics of extended-spectrum beta-lactamase resistance.
Niehus R; van Kleef E; Mo Y; Turlej-Rogacka A; Lammens C; Carmeli Y; Goossens H; Tacconelli E; Carevic B; Preotescu L; Malhotra-Kumar S; Cooper BS
Elife; 2020 May; 9():. PubMed ID: 32379042
[TBL] [Abstract][Full Text] [Related]
4. Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply "precision medicine" to antimicrobial chemotherapy?
Perez F; El Chakhtoura NG; Papp-Wallace KM; Wilson BM; Bonomo RA
Expert Opin Pharmacother; 2016; 17(6):761-81. PubMed ID: 26799840
[TBL] [Abstract][Full Text] [Related]
5. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa.
Kanj SS; Kanafani ZA
Mayo Clin Proc; 2011 Mar; 86(3):250-9. PubMed ID: 21364117
[TBL] [Abstract][Full Text] [Related]
6. Multicentre randomised controlled trial to investigate usefulness of the rapid diagnostic βLACTA test performed directly on bacterial cell pellets from respiratory, urinary or blood samples for the early de-escalation of carbapenems in septic intensive care unit patients: the BLUE-CarbA protocol.
Garnier M; Gallah S; Vimont S; Benzerara Y; Labbe V; Constant AL; Siami S; Guerot E; Compain F; Mainardi JL; Montil M; Quesnel C;
BMJ Open; 2019 Feb; 9(2):e024561. PubMed ID: 30782909
[TBL] [Abstract][Full Text] [Related]
7. Carbapenem or new β-lactam-β-lactamase inhibitors? An Italian survey supported by SITA, SIMIT and SIAARTI to identify the factors affecting empiric antimicrobial therapy choice in real-life clinical practice.
Colaneri M; Genovese C; Lombardi A; Holmes D; Bandera A; Gori A
Eur J Clin Microbiol Infect Dis; 2024 May; 43(5):1017-1023. PubMed ID: 38457097
[TBL] [Abstract][Full Text] [Related]
8. Available evidence of antibiotic resistance from extended-spectrum β-lactamase-producing Enterobacteriaceae in paediatric patients in 20 countries: a systematic review and meta-analysis.
Hu YJ; Ogyu A; Cowling BJ; Fukuda K; Pang HH
Bull World Health Organ; 2019 Jul; 97(7):486-501B. PubMed ID: 31258218
[TBL] [Abstract][Full Text] [Related]
9. Development of a prediction model for the acquisition of extended spectrum beta-lactam-resistant organisms in U.S. international travellers.
Brown DG; Worby CJ; Pender MA; Brintz BJ; Ryan ET; Sridhar S; Oliver E; Harris JB; Turbett SE; Rao SR; Earl AM; LaRocque RC; Leung DT
J Travel Med; 2023 Oct; 30(6):. PubMed ID: 36864572
[TBL] [Abstract][Full Text] [Related]
10. Which trial do we need? Piperacillin-tazobactam compared with a carbapenem for treatment of graft pyelonephritis caused by extended spectrum β-lactamase-producing Enterobacteriaceae.
Gueneau R; Henry B
Clin Microbiol Infect; 2023 Jul; 29(7):823-825. PubMed ID: 36958687
[No Abstract] [Full Text] [Related]
11. Resistance to β-lactams in
Poeys-Carvalho RMP; Gonzalez AGM
Crit Rev Food Sci Nutr; 2023 Nov; ():1-11. PubMed ID: 37999924
[TBL] [Abstract][Full Text] [Related]
12. In
Ouranos K; Mylonakis E
Ann Intern Med; 2024 May; 177(5):JC52. PubMed ID: 38710092
[TBL] [Abstract][Full Text] [Related]
13. Perturbation and resilience of the gut microbiome up to 3 months after β-lactams exposure in healthy volunteers suggest an important role of microbial β-lactamases.
d'Humières C; Delavy M; Alla L; Ichou F; Gauliard E; Ghozlane A; Levenez F; Galleron N; Quinquis B; Pons N; Mullaert J; Bridier-Nahmias A; Condamine B; Touchon M; Rainteau D; Lamazière A; Lesnik P; Ponnaiah M; Lhomme M; Sertour N; Devente S; Docquier JD; Bougnoux ME; Tenaillon O; Magnan M; Ruppé E; Grall N; Duval X; Ehrlich D; Mentré F; Denamur E; Rocha EPC; Le Chatelier E; Burdet C;
Microbiome; 2024 Mar; 12(1):50. PubMed ID: 38468305
[TBL] [Abstract][Full Text] [Related]
14. Successful prophylaxis of ESBL Enterobacteriaceae repetitive urinary tract infections with subcutaneous temocillin: a case report.
Delpierre E; Lanoix JP
JAC Antimicrob Resist; 2024 Feb; 6(1):dlad154. PubMed ID: 38186566
[TBL] [Abstract][Full Text] [Related]
15. Curbing gastrointestinal infections by defensin fragment modifications without harming commensal microbiota.
Koeninger L; Osbelt L; Berscheid A; Wendler J; Berger J; Hipp K; Lesker TR; Pils MC; Malek NP; Jensen BAH; Brötz-Oesterhelt H; Strowig T; Jan Wehkamp
Commun Biol; 2021 Jan; 4(1):47. PubMed ID: 33420317
[TBL] [Abstract][Full Text] [Related]
16. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
Harris PNA; Tambyah PA; Lye DC; Mo Y; Lee TH; Yilmaz M; Alenazi TH; Arabi Y; Falcone M; Bassetti M; Righi E; Rogers BA; Kanj S; Bhally H; Iredell J; Mendelson M; Boyles TH; Looke D; Miyakis S; Walls G; Al Khamis M; Zikri A; Crowe A; Ingram P; Daneman N; Griffin P; Athan E; Lorenc P; Baker P; Roberts L; Beatson SA; Peleg AY; Harris-Brown T; Paterson DL;
JAMA; 2018 Sep; 320(10):984-994. PubMed ID: 30208454
[TBL] [Abstract][Full Text] [Related]
17. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis.
Cassini A; Högberg LD; Plachouras D; Quattrocchi A; Hoxha A; Simonsen GS; Colomb-Cotinat M; Kretzschmar ME; Devleesschauwer B; Cecchini M; Ouakrim DA; Oliveira TC; Struelens MJ; Suetens C; Monnet DL;
Lancet Infect Dis; 2019 Jan; 19(1):56-66. PubMed ID: 30409683
[TBL] [Abstract][Full Text] [Related]
18. Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial.
Wittekamp BH; Plantinga NL; Cooper BS; Lopez-Contreras J; Coll P; Mancebo J; Wise MP; Morgan MPG; Depuydt P; Boelens J; Dugernier T; Verbelen V; Jorens PG; Verbrugghe W; Malhotra-Kumar S; Damas P; Meex C; Leleu K; van den Abeele AM; Gomes Pimenta de Matos AF; Fernández Méndez S; Vergara Gomez A; Tomic V; Sifrer F; Villarreal Tello E; Ruiz Ramos J; Aragao I; Santos C; Sperning RHM; Coppadoro P; Nardi G; Brun-Buisson C; Bonten MJM
JAMA; 2018 Nov; 320(20):2087-2098. PubMed ID: 30347072
[TBL] [Abstract][Full Text] [Related]
19. The Infinity War: How to Cope with Carbapenem-resistant
Yoo JH
J Korean Med Sci; 2018 Oct; 33(40):e255. PubMed ID: 30275806
[TBL] [Abstract][Full Text] [Related]
20. Plasmid-mediated resistance is going wild.
Dolejska M; Papagiannitsis CC
Plasmid; 2018 Sep; 99():99-111. PubMed ID: 30243983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
